Targeting these interactions could hold promise for developing therapeutic strategies aimed at mitigating the progression of diseases like Alzheimer’s, FTD, and ALS, where Tau and TDP-43 play central roles in pathology. Here, MAPT is linked to frontotemporal dementia.